Gene therapy is a rapidly progressing field that holds immense potential for treating conditions that were previously considered untreatable. Although only a few gene therapies have gained approval to date, the U.S. Food and Drug Administration (FDA) predicts a significant increase in approvals, estimating around 10 to 20 cell and gene therapies per year by 2025. These innovative treatments offer hope for patients and their families, representing a new era in healthcare. However, it is important to note that the approved therapies are costly, with prices exceeding $2 million for a single dose. This pricing trend is expected to continue for future gene therapies, which could have significant immediate and long-term impacts on clients and the healthcare system. Currently, the FDA has approved 27 cellular and gene therapies, with several more expected to be approved in the near future.
AcceGen offers a comprehensive service for the development of Gene & Cell Therapy research. From antibody development to gene delivery, immune cell engineering, and phenotype testing, we provide tailored solutions at every stage of the drug development journey.
AcceGen offers customizable viral vector packaging services, including AAV, lentivirus, adenovirus, and retrovirus packaging. We provide flexibility in using our transfer vectors, custom-designed vectors, or your own vectors. Our catalog also provides a large number of ready-to-use viral vectors for your research applications.
View our Virus Vector Packaging Portfolio
AcceGen offers comprehensive gene editing services, including gene knock-out protocols and customized approaches for complex projects. With rigorous quality control and a range of techniques, researchers can gain valuable insights into disease mechanisms and potential therapeutic targets.
View our Genome Editing Portfolio
AcceGen offers comprehensive stable cell line services for gene overexpression and knockout, supporting drug screening, gene functional studies, and ensuring monoclonality. With advanced techniques and testing services, researchers gain valuable insights into drug efficacy, gene functions, and antibody production.
View our Cells Line Construction Portfolio
AcceGen offers a diverse range of animal models to support research in cellular therapy and gene therapy advancements. Our models, including immunodeficient rodents and large animals, provide valuable insights into disease mechanisms, drug development, and gene modification studies.
View our Animal Models Portfolio
AcceGen collaborates with brokers to provide invaluable assistance to their clients in navigating the future of gene therapy. We provide comprehensive risk-management programs and strategies, empowering our retail partners with the necessary knowledge and expertise to adapt to the complex and ever-changing gene therapy landscape. Our goal is to offer meaningful solutions that safeguard employers in this rapidly evolving field.